Application of Immune Checkpoint Inhibitors for Resectable Gastric/gastroesophageal Cancer

Overview

Journal Front Pharmacol

Date 2024 May 24

PMID 38783944

Authors

Feizhi Lin

Yongming Chen

Bowen Huang

Shenghang Ruan

Jun Lin

Zewei Chen

Chunyu Huang

Baiwei Zhao

Affiliations

Soon will be listed here.

Abstract

Gastric/gastroesophageal junction (G/GEJ) cancer represents a significant global health challenge. Radical surgery remains the cornerstone of treatment for resectable G/GEJ cancer. Supported by robust evidence from multiple clinical studies, therapeutic approaches, including adjuvant chemotherapy or chemoradiation, and perioperative chemotherapy, are generally recommended to reduce the risk of recurrence and enhance long-term survival outcomes post-surgery. In recent years, immune checkpoint inhibitors (ICIs) have altered the landscape of systemic treatment for advanced or metastatic G/GEJ cancer, becoming the standard first-line therapy for specific patients. Consequently, exploring the efficacy of ICIs in the adjuvant or neoadjuvant setting for resectable G/GEJ cancer is worthwhile. This review summarizes the current advances in the application of ICIs for resectable G/GEJ cancer.

Citing Articles

ALKBH5 suppresses gastric cancer tumorigenesis and metastasis by inhibiting the translation of uncapped WRAP53 RNA isoforms in an m6A-dependent manner.

Zheng Z, Lin F, Zhao B, Chen G, Wei C, Chen X Mol Cancer. 2025; 24(1):19.

PMID: 39815301 PMC: 11734446. DOI: 10.1186/s12943-024-02223-4.

PI3K/AKT/mTOR and PD‑1/CTLA‑4/CD28 pathways as key targets of cancer immunotherapy (Review).

Wang S, Liu C, Yang C, Jin Y, Cui Q, Wang D Oncol Lett. 2024; 28(6):567.

PMID: 39390982 PMC: 11465225. DOI: 10.3892/ol.2024.14700.

References

Yoon H, Jin Z, Kour O, Kankeu Fonkoua L, Shitara K, Gibson M . Association of PD-L1 Expression and Other Variables With Benefit From Immune Checkpoint Inhibition in Advanced Gastroesophageal Cancer: Systematic Review and Meta-analysis of 17 Phase 3 Randomized Clinical Trials. JAMA Oncol. 2022; 8(10):1456-1465. PMC: 9412834. DOI: 10.1001/jamaoncol.2022.3707. View

Han C, Zhan Q . Precision medicine revolutionizes cancer diagnosis and treatment. Med Rev (2021). 2023; 2(6):541-543. PMC: 10471116. DOI: 10.1515/mr-2022-0041. View

Ajani J, DAmico T, Bentrem D, Chao J, Cooke D, Corvera C . Gastric Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2022; 20(2):167-192. DOI: 10.6004/jnccn.2022.0008. View

Shrimali R, Yu Z, Theoret M, Chinnasamy D, Restifo N, Rosenberg S . Antiangiogenic agents can increase lymphocyte infiltration into tumor and enhance the effectiveness of adoptive immunotherapy of cancer. Cancer Res. 2010; 70(15):6171-80. PMC: 2912959. DOI: 10.1158/0008-5472.CAN-10-0153. View

Smith D, Schwarz R, Schwarz R . Impact of total lymph node count on staging and survival after gastrectomy for gastric cancer: data from a large US-population database. J Clin Oncol. 2005; 23(28):7114-24. DOI: 10.1200/JCO.2005.14.621. View

Siegel R, Miller K, Fuchs H, Jemal A . Cancer Statistics, 2021. CA Cancer J Clin. 2021; 71(1):7-33. DOI: 10.3322/caac.21654. View

Marin-Acevedo J, Kimbrough E, Lou Y . Next generation of immune checkpoint inhibitors and beyond. J Hematol Oncol. 2021; 14(1):45. PMC: 7977302. DOI: 10.1186/s13045-021-01056-8. View

Sasako M, Sakuramoto S, Katai H, Kinoshita T, Furukawa H, Yamaguchi T . Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer. J Clin Oncol. 2011; 29(33):4387-93. DOI: 10.1200/JCO.2011.36.5908. View

Catenacci D, Chase L, Lomnicki S, Karrison T, de Wilton Marsh R, Rampurwala M . Evaluation of the Association of Perioperative UGT1A1 Genotype-Dosed gFOLFIRINOX With Margin-Negative Resection Rates and Pathologic Response Grades Among Patients With Locally Advanced Gastroesophageal Adenocarcinoma: A Phase 2 Clinical Trial. JAMA Netw Open. 2020; 3(2):e1921290. DOI: 10.1001/jamanetworkopen.2019.21290. View

10.

Lordick F, Carneiro F, Cascinu S, Fleitas T, Haustermans K, Piessen G . Gastric cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2022; 33(10):1005-1020. DOI: 10.1016/j.annonc.2022.07.004. View

11.

Bagchi S, Yuan R, Engleman E . Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance. Annu Rev Pathol. 2020; 16:223-249. DOI: 10.1146/annurev-pathol-042020-042741. View

12.

Park S, Lim D, Sohn T, Lee J, Zang D, Kim S . A randomized phase III trial comparing adjuvant single-agent S1, S-1 with oxaliplatin, and postoperative chemoradiation with S-1 and oxaliplatin in patients with node-positive gastric cancer after D2 resection: the ARTIST 2 trial. Ann Oncol. 2020; 32(3):368-374. DOI: 10.1016/j.annonc.2020.11.017. View

13.

Bang Y, Van Cutsem E, Feyereislova A, Chung H, Shen L, Sawaki A . Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010; 376(9742):687-97. DOI: 10.1016/S0140-6736(10)61121-X. View

14.

McLaughlin M, Patin E, Pedersen M, Wilkins A, Dillon M, Melcher A . Inflammatory microenvironment remodelling by tumour cells after radiotherapy. Nat Rev Cancer. 2020; 20(4):203-217. DOI: 10.1038/s41568-020-0246-1. View

15.

Lin Q, Wang X, Hu Y . The opportunities and challenges in immunotherapy: Insights from the regulation of PD-L1 in cancer cells. Cancer Lett. 2023; 569:216318. DOI: 10.1016/j.canlet.2023.216318. View

16.

Li J, Qin S, Xu J, Xiong J, Wu C, Bai Y . Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction. J Clin Oncol. 2016; 34(13):1448-54. DOI: 10.1200/JCO.2015.63.5995. View

17.

Andre T, Tougeron D, Piessen G, De La Fouchardiere C, Louvet C, Adenis A . Neoadjuvant Nivolumab Plus Ipilimumab and Adjuvant Nivolumab in Localized Deficient Mismatch Repair/Microsatellite Instability-High Gastric or Esophagogastric Junction Adenocarcinoma: The GERCOR NEONIPIGA Phase II Study. J Clin Oncol. 2022; 41(2):255-265. PMC: 9839243. DOI: 10.1200/JCO.22.00686. View

18.

Sun W, Veeramachaneni N, Al-Rajabi R, Madan R, Kasi A, Al-Kasspooles M . A phase II study of perioperative pembrolizumab plus mFOLFOX in patients with potentially resectable esophagus, gastroesophageal junction (GEJ), and stomach adenocarcinoma. Cancer Med. 2023; 12(15):16098-16107. PMC: 10469814. DOI: 10.1002/cam4.6263. View

19.

Mole R . Whole body irradiation; radiobiology or medicine?. Br J Radiol. 1953; 26(305):234-41. DOI: 10.1259/0007-1285-26-305-234. View

20.

. Japanese Gastric Cancer Treatment Guidelines 2021 (6th edition). Gastric Cancer. 2022; 26(1):1-25. DOI: 10.1007/s10120-022-01331-8. View